Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DOVATO safely and effectively. See full prescribing information for DOVATO. DOVATO (dolutegravir and lamivudine) tablets, for oral useInitial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO.
- generic_name
- dolutegravir sodium and lamivudine
- product_names
- dolutegravir sodium and lamivudine
- ndc
- 49702-246, 49702-246-13, 49702-246-33, 49702-246-62
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en